Trinity biotech announces q3 2024 financial results

Q3 2024 total revenue of $15.2 million grew +3% y/y based on strong demand and output in the trinscreen hiv business point-of-care product revenue of $4.3 million grew 60% y/y reiterates guidance to achieve approximately $20 million of annualized run-rate ebitdaso1 on annualized run-rate revenues of approximately $75 million by q2 2025 reiterates guidance to achieve 2024 sales revenue for trinscreen hiv of approximately $10 million dublin, nov. 15, 2024 (globe newswire) -- trinity biotech plc (nasdaq: trib), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced the company's results for the quarter ended september 30, 2024. key highlights and developments continued revenue and profitability improvements year-over-year revenue growth of 3% and continued disciplined execution on our profitability enhancing initiatives contributed to a decrease in the operating loss (before restructuring and impairment charges) to $2.2 million from $4.5m in q3 2023, a 51% improvement.
TRIB Ratings Summary
TRIB Quant Ranking